IL2112 / Ildong - LARVOL DELTA

Ildong Pharm Group's pulmonary fibrosis drug candidate wins US orphan drug designation (Korea Biomedical Review) - "IL21120033, a new drug candidate being developed by iLeadBMS...received an Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for treating idiopathic pulmonary fibrosis (IPF)....'As the FDA’s orphan drug designation recognizes the potential for new drug development, we will accelerate further development, including safety evaluation and clinical trial plan approval.'"

Orphan drug • Idiopathic Pulmonary Fibrosis